Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
Open Access
- 1 July 2019
- journal article
- research article
- Published by Bioscientifica in Endocrine Connections
- Vol. 8 (7) , 988-996
Abstract
Objective: To investigate the mutant status of BRAF gene and analyze its relationship to epidemiological risk factors and clinical outcomes among patients with papillary thyroid cancer (PTC) in the largest, single-institution Chinese cohort to date. Methods: The medical records of 2048 PTC patients were reviewed in this retrospective study. Single-factor and multiple logistic regression analyses were applied to identify risk factors for BRAF V600E mutation. Survival outcomes including distant metastatic and persistent or recurrent PTC were examined, with a mean follow-up time of 23.4 (5–47) months. Results: The BRAF V600E mutation was present in 83.7% of patients (1715 of 2048). Correlation was found between BRAF V600E mutation and several epidemiological features, including age, concomitant hypertension and Hashimoto thyroiditis (HT). For the clinicopathological features, BRAF V600E was significantly associated with bilateral multifocality (odds ratio (OR) 1.233, 95% confidence interval (CI) 1.063–1.431, P < 0.01) and less lateral lymph node metastases (OR 0.496, 95% CI 0.357–0.689, P < 0.01). Smaller tumor size and advanced disease stage were significant in single-factor analyses but became insignificant after multivariate adjustment. No association was found between BRAF V600E mutation and extrathyroidal invasion, distant metastatic and disease persistence or recurrence. Conclusion: Part of epidemiological features are independent risk or protective factors for BRAF V600E mutation. The presence of BRAF V600E mutation is not an aggressive prognosis on poor clinical outcomes in PTC. However, the high prevalence of BRAF V600E may provide guidance for surgery strategy and opportunity for targeted treatment in recurrent and advanced stage disease.Keywords
This publication has 31 references indexed in Scilit:
- Thyroid surgery for differentiated thyroid cancer — recent advances and future directionsNature Reviews Endocrinology, 2018
- Thyroid Autoimmunity and Thyroid Cancer: Review Focused on Cytological StudiesEuropean Thyroid Journal, 2017
- Meta-Analyses of Association Between BRAFV600E Mutation and Clinicopathological Features of Papillary Thyroid CarcinomaCellular Physiology and Biochemistry, 2016
- BRAF mutation is not predictive of long‐term outcome in papillary thyroid carcinomaCancer Medicine, 2015
- Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?Trends in Endocrinology & Metabolism, 2014
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialThe Lancet, 2014
- The BRAFV600E mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?Clinical Endocrinology, 2014
- Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid CancerJAMA, 2013
- The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancerCancer, 2011
- The Prevalence and Prognostic Value of BRAF Mutation in Thyroid CancerAnnals of Surgery, 2007